Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis

ConclusionIn postmenopausal women with estrogen and/or progesterone receptor-positive advanced breast cancer, fulvestrant 500  mg showed better efficacy than aromatase inhibitor, which was not seen with fulvestrant 250 mg. Compared to aromatase inhibitors, fulvestrant prolonged time to progression/progression-free survival in the subgroups including estrogen and progesterone receptor-positive patients and those aged ≥  65 years.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research